Penicillin Allergy De-Labelling in Elective Surgical Patients (PADLES) (PADLES)
Primary Purpose
Allergy
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Amoxicillin
Sponsored by
About this trial
This is an interventional diagnostic trial for Allergy
Eligibility Criteria
Inclusion Criteria:
- Allergic history is historic (more than 10 years ago) and suggestive of a non-immediate reaction or side effect
- Requires penicillin as first-line treatment for their planned surgery
- >18 years
- Willing and able to give consent
Exclusion Criteria:
- Not willing to participate
- History suggestive of immediate type reaction (anaphylaxis)
- History of toxic epidermal necrolysis or Stevens Johnson syndrome
- Pregnant, planning to become pregnant during study, or breastfeeding
Sites / Locations
- Leeds Teaching Hospitals NHS Trust
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Group 1 - Interventional Treatment
Arm Description
A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows: 50mg amoxicillin (10% total dose) 250mg amoxicillin (50% total dose) 200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available.
Outcomes
Primary Outcome Measures
Completion of the study questionnaire by participants
Online questionnaire about previously diagnosed allergies to be completed by study participants
Secondary Outcome Measures
Full Information
NCT ID
NCT03607734
First Posted
June 27, 2018
Last Updated
July 23, 2018
Sponsor
The Leeds Teaching Hospitals NHS Trust
1. Study Identification
Unique Protocol Identification Number
NCT03607734
Brief Title
Penicillin Allergy De-Labelling in Elective Surgical Patients (PADLES)
Acronym
PADLES
Official Title
Penicillin Allergy De-Labelling in Elective Surgical Patients - A Study to Determine the Safety, Efficacy and Feasibility of Abbreviated Allergy Testing
Study Type
Interventional
2. Study Status
Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
April 24, 2017 (Actual)
Primary Completion Date
October 2, 2017 (Actual)
Study Completion Date
October 2, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Leeds Teaching Hospitals NHS Trust
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Penicillin antibiotics are safe and inexpensive, and target selected bacteria rather than killing a broad range. Unfortunately, around 10% of the population are labelled as 'penicillin allergic'. This is often based on side effects such as rash and diarrhoea, and 90-95% of people with the label are not actually allergic to the drug.
The label leads to the use of alternative antibiotics, which tend to more toxic, and less specific about which bacteria they kill; this increases the risk of infections with so-called 'super-bugs', compared to patients without the label. People with the label also have an increased length of hospital stay and rates of readmission. These are significant problems for individuals, as well as wider society. Where the diagnosis is in doubt, the gold standard test for allergy is an oral challenge. Patients undergo skin +/- blood tests prior to a challenge, as these can help make the diagnosis. This combined pathway is expensive and time consuming, so testing cannot be offered routinely to all patients. However in patients with 'historic' reactions (many years previously), skin and blood tests become much less useful; in one study, 100% of patients who skin tested positive for amoxycillin allergy, tested negative 5 years later. Patients with historic reactions can therefore proceed directly to an oral challenge without prior skin or blood testing, since these offer little help in making the diagnosis. This streamlines the pathway, making it quick, non-invasive and cheap. Already established practice in several centres in Europe and beyond, this abbreviated pathway is offered on an ad-hoc basis in some centres in the UK.
The aim is to demonstrate that this pathway offers a safe and effective way to perform large-scale delabelling of elective surgical patients, who might not otherwise meet NICE criteria for testing.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Allergy
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
150 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group 1 - Interventional Treatment
Arm Type
Other
Arm Description
A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:
50mg amoxicillin (10% total dose)
250mg amoxicillin (50% total dose)
200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available.
Intervention Type
Drug
Intervention Name(s)
Amoxicillin
Intervention Description
A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:
50mg amoxicillin (10% total dose)
250mg amoxicillin (50% total dose)
200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available.
Primary Outcome Measure Information:
Title
Completion of the study questionnaire by participants
Description
Online questionnaire about previously diagnosed allergies to be completed by study participants
Time Frame
1 day
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Allergic history is historic (more than 10 years ago) and suggestive of a non-immediate reaction or side effect
Requires penicillin as first-line treatment for their planned surgery
>18 years
Willing and able to give consent
Exclusion Criteria:
Not willing to participate
History suggestive of immediate type reaction (anaphylaxis)
History of toxic epidermal necrolysis or Stevens Johnson syndrome
Pregnant, planning to become pregnant during study, or breastfeeding
Facility Information:
Facility Name
Leeds Teaching Hospitals NHS Trust
City
Leeds
ZIP/Postal Code
LS9 7TF
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Penicillin Allergy De-Labelling in Elective Surgical Patients (PADLES)
We'll reach out to this number within 24 hrs